$APDN
APPLIED DNA SCIENCES INC

2023 Q2 Form 10-Q Financial Statement

#000141057823001014 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $2.917M $4.408M
YoY Change -32.1% -28.3%
Cost Of Revenue $1.648M $2.600M
YoY Change -49.4% -28.93%
Gross Profit $1.269M $1.807M
YoY Change 22.14% -27.37%
Gross Profit Margin 43.51% 41.01%
Selling, General & Admin $3.292M $3.523M
YoY Change 9.23% 3.22%
% of Gross Profit 259.38% 194.9%
Research & Development $836.1K $988.7K
YoY Change -3.12% -7.6%
% of Gross Profit 65.87% 54.7%
Depreciation & Amortization $349.1K $344.5K
YoY Change 8.71% 7.36%
% of Gross Profit 27.51% 19.06%
Operating Expenses $4.128M $4.511M
YoY Change 6.49% 0.64%
Operating Profit -$2.859M -$2.704M
YoY Change 0.75% 35.59%
Interest Expense $26.78K $3.640K
YoY Change -34.3%
% of Operating Profit
Other Income/Expense, Net -$3.469K $661.00
YoY Change -92.34% -100.41%
Pretax Income -$3.114M $551.2K
YoY Change 176.87% -131.32%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$3.100M $588.3K
YoY Change 175.73% -133.45%
Net Earnings / Revenue -106.25% 13.35%
Basic Earnings Per Share -$0.24 $0.05
Diluted Earnings Per Share -$0.24 $0.05
COMMON SHARES
Basic Shares Outstanding 12.91M 12.91M
Diluted Shares Outstanding 12.91M 12.91M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.76M $12.29M
YoY Change 129.74% 88.66%
Cash & Equivalents $10.76M $12.29M
Short-Term Investments
Other Short-Term Assets $524.9K $758.5K
YoY Change -5.36% 17.79%
Inventory $276.4K $366.1K
Prepaid Expenses
Receivables $682.7K $1.968M
Other Receivables $0.00 $0.00
Total Short-Term Assets $12.24M $15.38M
YoY Change 32.07% 37.87%
LONG-TERM ASSETS
Property, Plant & Equipment $1.168M $1.575M
YoY Change -54.33% -40.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.026M $750.0K
YoY Change 979.94% 689.31%
Total Long-Term Assets $3.549M $3.796M
YoY Change 33.81% 39.37%
TOTAL ASSETS
Total Short-Term Assets $12.24M $15.38M
Total Long-Term Assets $3.549M $3.796M
Total Assets $15.79M $19.18M
YoY Change 32.46% 38.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.052M $1.647M
YoY Change -42.89% 14.61%
Accrued Expenses $1.564M $1.725M
YoY Change -7.23% -4.3%
Deferred Revenue $275.9K $283.3K
YoY Change -63.57% -28.03%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.891M $3.655M
YoY Change -32.52% 0.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.704M $5.552M
YoY Change 578.13% 113.59%
Total Long-Term Liabilities $5.704M $5.552M
YoY Change 578.13% 113.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.891M $3.655M
Total Long-Term Liabilities $5.704M $5.552M
Total Liabilities $8.595M $9.207M
YoY Change 67.7% 47.72%
SHAREHOLDERS EQUITY
Retained Earnings -$298.9M -$295.8M
YoY Change 2.4% 1.73%
Common Stock $306.1M $305.8M
YoY Change 2.5% 2.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.249M $10.01M
YoY Change
Total Liabilities & Shareholders Equity $15.79M $19.18M
YoY Change 32.46% 38.16%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$3.100M $588.3K
YoY Change 175.73% -133.45%
Depreciation, Depletion And Amortization $349.1K $344.5K
YoY Change 8.71% 7.36%
Cash From Operating Activities -$1.369M $214.4K
YoY Change -21.95% -181.86%
INVESTING ACTIVITIES
Capital Expenditures $24.20K $54.34K
YoY Change -131.56% -182.92%
Acquisitions
YoY Change
Other Investing Activities -$137.6K $0.00
YoY Change
Cash From Investing Activities -$161.8K -$54.34K
YoY Change 111.03% -17.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -1.369M 214.4K
Cash From Investing Activities -161.8K -54.34K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -1.531M 160.0K
YoY Change -16.38% -95.75%
FREE CASH FLOW
Cash From Operating Activities -$1.369M $214.4K
Capital Expenditures $24.20K $54.34K
Free Cash Flow -$1.393M $160.0K
YoY Change -16.94% -181.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12908520
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8084680
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12908520
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7783747
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12908520
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12908520
dei Entity Central Index Key
EntityCentralIndexKey
0000744452
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2023Q1 apdn Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q1 apdn Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2023Q1 apdn Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36745
dei Entity Registrant Name
EntityRegistrantName
Applied DNA Sciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-2262718
dei Entity Address Address Line1
EntityAddressAddressLine1
50 Health Sciences Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Stony Brook
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11790
dei City Area Code
CityAreaCode
631
dei Local Phone Number
LocalPhoneNumber
240-8800
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
APDN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12908520
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12287228
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15215285
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
40831
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
330853
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1967710
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3067544
CY2023Q1 us-gaap Inventory Net
InventoryNet
366085
CY2022Q3 us-gaap Inventory Net
InventoryNet
602244
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
758530
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1058056
CY2023Q1 us-gaap Assets Current
AssetsCurrent
15379553
CY2022Q3 us-gaap Assets Current
AssetsCurrent
19943129
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1575309
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2222988
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1470615
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
98997
CY2023Q1 us-gaap Assets
Assets
19175477
CY2022Q3 us-gaap Assets
Assets
22265114
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2895578
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3621751
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
476502
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
283298
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
563557
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3655378
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4185308
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
994111
CY2023Q1 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
4526300
CY2022Q3 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
5139400
CY2023Q1 us-gaap Liabilities
Liabilities
9207256
CY2022Q3 us-gaap Liabilities
Liabilities
9356175
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12908520
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12908520
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
12909
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
12909
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
305751360
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
305399008
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295755117
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292500088
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10009152
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12911829
CY2023Q1 us-gaap Minority Interest
MinorityInterest
-40931
CY2022Q3 us-gaap Minority Interest
MinorityInterest
-2890
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6480708
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Profit Loss
ProfitLoss
551176
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-1759797
us-gaap Profit Loss
ProfitLoss
-3293070
us-gaap Profit Loss
ProfitLoss
-6480708
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-37167
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1112
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-38041
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9968221
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19175477
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22265114
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4407614
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6147283
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9670366
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10312989
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
2600179
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
3658798
us-gaap Cost Of Revenue
CostOfRevenue
5485248
us-gaap Cost Of Revenue
CostOfRevenue
6715366
CY2023Q1 us-gaap Gross Profit
GrossProfit
1807435
CY2022Q1 us-gaap Gross Profit
GrossProfit
2488485
us-gaap Gross Profit
GrossProfit
4185118
us-gaap Gross Profit
GrossProfit
3597623
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3522715
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3572680
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6148072
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8308299
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
988744
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1070041
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1960048
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2150137
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4511459
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
4642721
us-gaap Operating Expenses
OperatingExpenses
8108120
us-gaap Operating Expenses
OperatingExpenses
10458436
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2704024
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2154236
us-gaap Operating Income Loss
OperatingIncomeLoss
-3923002
us-gaap Operating Income Loss
OperatingIncomeLoss
-6860813
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3639
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5540
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7325
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5813
CY2023Q1 apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
0
CY2022Q1 apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-391335
apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-391335
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3250900
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-782500
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-613100
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-782500
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
661
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2266
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9507
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16873
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
551176
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1759797
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3293070
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-257
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
588343
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1758685
us-gaap Net Income Loss
NetIncomeLoss
-3255029
us-gaap Net Income Loss
NetIncomeLoss
-6480451
CY2023Q1 apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
0
CY2022Q1 apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
110105
apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
110105
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
588343
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1868790
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3255029
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6590556
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12908520
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8084680
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12908520
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7783747
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
93748
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3844246
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9158441
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
258604
CY2023Q1 us-gaap Profit Loss
ProfitLoss
551176
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9968221
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11112946
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1699920
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
300000
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-4720911
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8391955
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
272915
CY2022Q1 apdn Shares Issued In Public Offering
SharesIssuedInPublicOffering
-4091833
CY2022Q1 apdn Warrants Issued During Period Value Warrants
WarrantsIssuedDuringPeriodValueWarrants
-3350400
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-1759797
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7646506
us-gaap Profit Loss
ProfitLoss
-3293070
us-gaap Profit Loss
ProfitLoss
-6480708
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
683422
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
641615
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
6083
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-613100
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-782500
us-gaap Share Based Compensation
ShareBasedCompensation
352352
us-gaap Share Based Compensation
ShareBasedCompensation
1972835
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-290022
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
10000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1389855
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-206227
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-236159
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-725965
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-398523
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
842071
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-746495
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
472201
apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
-280259
apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
112656
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2168718
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3963780
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54339
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
170217
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9339
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-170217
apdn Net Proceeds From Sale Of Common Stock And Warrants
NetProceedsFromSaleOfCommonStockAndWarrants
0
apdn Net Proceeds From Sale Of Common Stock And Warrants
NetProceedsFromSaleOfCommonStockAndWarrants
4091833
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4091833
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2178057
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42164
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15215285
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6554948
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13037228
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6512784
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
apdn Property Plant And Equipment Acquired And Included In Accounts Payable
PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable
20321
apdn Property Plant And Equipment Acquired And Included In Accounts Payable
PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable
76178
apdn Deemed Dividend Warrant Modifications
DeemedDividendWarrantModifications
0
apdn Deemed Dividend Warrant Modifications
DeemedDividendWarrantModifications
110105
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1545916
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
apdn Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
0
apdn Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
3350400
apdn Issuance Of Stock Options Issued For Payment Of Accrued Bonus
IssuanceOfStockOptionsIssuedForPaymentOfAccruedBonus
0
apdn Issuance Of Stock Options Issued For Payment Of Accrued Bonus
IssuanceOfStockOptionsIssuedForPaymentOfAccruedBonus
300000
apdn Number Of Primary Markets That Use Company S Technologies
NumberOfPrimaryMarketsThatUseCompanySTechnologies
3
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295755117
us-gaap Profit Loss
ProfitLoss
-3293070
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2168718
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12287228
CY2023Q1 apdn Working Capital Surplus Deficit
WorkingCapitalSurplusDeficit
11724175
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates include revenue recognition, recoverability of long-lived assets, including the values assigned to property and equipment, fair value calculations for warrants, contingencies, and management’s anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates. </p>
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4407614
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6147283
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9670366
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10312989
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15215285
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
280259
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2082
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
343367
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9784564
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3307577
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12287228
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
750000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13037228
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15215285
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. As of March 31, 2023, the Company had cash and cash equivalents of approximately $11.6 million in excess of the FDIC insurance limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s revenues earned from sale of products and services for the three and six-month periods ended March 31, 2023 included an aggregate of 85% and 84%, respectively from two customers within the MDx Testing Services segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Two customers from within the MDx Testing Services segment accounted for 53% and 14%, respectively of the Company’s revenues earned from sale of products and services for the three-month period ended March 31, 2022. One customer from within the MDx Testing Services segment accounted for 51% of the Company's revenues earned from sales of products and services for the six-month period ended March 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Two customers accounted for 86% of the Company’s accounts receivable at March 31, 2023 and two customers accounted for 89% of the Company’s accounts receivable at September 30, 2022.</p>
CY2023Q1 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
11600000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q1 apdn Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
305775
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
471947
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
26425
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
55817
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
33885
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
74480
CY2023Q1 us-gaap Inventory Net
InventoryNet
366085
CY2022Q3 us-gaap Inventory Net
InventoryNet
602244
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1647164
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1744105
CY2023Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
789199
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1458661
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
459215
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
418985
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2895578
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3621751
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7313963
CY2022Q3 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
3.68
apdn Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
18375
apdn Weighted Average Price Per Share Warrant Cancelled Or Expired
WeightedAveragePricePerShareWarrantCancelledOrExpired
17.60
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7295588
CY2023Q1 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
3.65
CY2013Q2 apdn Area Of Property Under Operating Lease
AreaOfPropertyUnderOperatingLease
30000
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2023Q1 apdn Area Of Laboratory Space
AreaOfLaboratorySpace
2500
CY2017Q4 apdn Lease For Satellite Testing
LeaseForSatelliteTesting
1108
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2017Q4 apdn Base Rent During Initial Lease Term
BaseRentDuringInitialLeaseTerm
6500
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
165871
us-gaap Operating Lease Expense
OperatingLeaseExpense
314697
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
97722
us-gaap Operating Lease Cost
OperatingLeaseCost
97722
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
68149
us-gaap Short Term Lease Cost
ShortTermLeaseCost
216975
CY2023Q1 us-gaap Lease Cost
LeaseCost
165871
us-gaap Lease Cost
LeaseCost
314697
us-gaap Operating Lease Payments
OperatingLeasePayments
97722
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1545916
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
293167
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
586334
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
586334
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
195445
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1661280
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
190667
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1470613
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4407614
CY2023Q1 us-gaap Gross Profit
GrossProfit
1807435
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6147283
CY2022Q1 us-gaap Gross Profit
GrossProfit
2488485
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9670366
us-gaap Gross Profit
GrossProfit
4185118
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10312989
us-gaap Gross Profit
GrossProfit
3597623
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3639
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5540
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3250900
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-782500
CY2022Q1 apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-391335
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
661
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2266
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
551176
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1759797
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7325
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5813
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-613100
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-782500
apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-391335
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9507
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16873
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3293070
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6480708

Files In Submission

Name View Source Status
apdn-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apdn-20230331_pre.xml Edgar Link unprocessable
0001410578-23-001014-index-headers.html Edgar Link pending
0001410578-23-001014-index.html Edgar Link pending
0001410578-23-001014.txt Edgar Link pending
0001410578-23-001014-xbrl.zip Edgar Link pending
apdn-20230331.xsd Edgar Link pending
apdn-20230331x10q.htm Edgar Link pending
apdn-20230331x10q_htm.xml Edgar Link completed
apdn-20230331xex31d1.htm Edgar Link pending
apdn-20230331xex31d2.htm Edgar Link pending
apdn-20230331xex32d1.htm Edgar Link pending
apdn-20230331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
apdn-20230331_def.xml Edgar Link unprocessable
apdn-20230331_lab.xml Edgar Link unprocessable
Show.js Edgar Link pending